Esteban Ribera Pascuet-rekin lankidetzan egindako argitalpenak (11)

2017

  1. Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach

    PLoS ONE, Vol. 12, Núm. 9

2016

  1. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

2013

  1. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies

    AIDS, Vol. 27, Núm. 1, pp. 81-85

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 8, pp. 2020-2028

  3. Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations

    AIDS Research and Human Retroviruses, Vol. 28, Núm. 2, pp. 156-164

2010

  1. Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

    AIDS, Vol. 24, Núm. 3, pp. 469-471

2009

  1. (Enfermedades Infecciosas y Microbiologia Clinica (2009) 27, 4, (222-235))

    Enfermedades Infecciosas y Microbiologia Clinica

2008

  1. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens

    HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313

2007

  1. Recomendaciones españolas sobre el uso adecuado de enfuvirtida

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 25, Núm. 2, pp. 131-142

  2. Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment

    Expert Opinion on Pharmacotherapy, Vol. 8, Núm. 5, pp. 679-688